News + Font Resize -

SkyePharma to receive milestone payment from Endo for Propofol IDD-D
London | Saturday, April 10, 2004, 08:00 Hrs  [IST]

SkyePharma PLC announces that it has successfully completed the review of the Phase II trial results of Propofol IDD-D with the US Food & Drug Administration (FDA). Propofol IDD-D is licensed in North America to Endo Pharmaceuticals and, under the terms of the December 2002 agreement as amended between SkyePharma and Endo, a US$5 million milestone payment to SkyePharma is now due.

SkyePharma and Endo have agreed upon the Phase III trial programme and expect Propofol IDD-D to commence Phase III trials around the middle of this year.

Propofol IDD-D is a 2 per cent intravenous formulation of propofol as the sole active ingredient and employs SkyePharma's patented Insoluble Drug Delivery (IDD-D technology. In contrast with currently marketed versions of propofol, SkyePharma believes that Propofol IDD-D will not support significant microbial growth and therefore will not require incorporation of a preservative. Propofol IDD-D is intended for the maintenance of anaesthesia in adults during surgery and for sedation of adults hospitalized in an intensive-care setting.

Propofol IDD-D has been studied in a Phase II clinical trial. The study, involving 79 female patients undergoing laparoscopic gynaecological surgery, was designed to show clinical effect of Propofol IDD-D versus AstraZeneca's Diprivan, a currently marketed version of 1 per cent propofol. The study results provided evidence of comparable pharmacokinetics, efficacy and safety of the two formulations which will need to be confirmed in phase III trials.

Post Your Comment

 

Enquiry Form